Your trusted source for GLP-1 research, news, and patient insights.
9 posts in this category
Wegovy HD (7.2 mg) is now FDA-approved with 20.7% average weight loss. Learn about results, effects, availability, and how it compares to Zepbound.
FDA warned 30 telehealth companies over GLP-1 marketing claims. Learn what changed, why compounding is not going away, and what to look for.
The FDA warned Novo Nordisk for not reporting deaths and serious side effects tied to its GLP-1 medications. Here is what happened.
India’s GLP-1 patent expiry may lower prices there first. Learn what it could mean for US access and affordability.
Hearing new GLP-1 names? Learn why language changed, what stayed the same, and how to tell if your medication actually changed.
Learn how to identify fake Ozempic, check packaging and lot numbers, and avoid online GLP-1 scams. Simple safety tips for families.
Latest updates on Indiana, Florida, and federal GLP-1 compounding laws and what the changes could mean for patient access in 2026.
We're working hard to keep things updated but give us some grace as providers potentially change their offerings around tirzepatide.
We’ve all been hearing about the shortage of tirzepatide or semaglutide, but what is a shortage? How does it impact compounding?
